Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCbHP vs EC-THP in HER2-positive Early Breast Cancer
NCT05883852Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- Jul 2031
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin in HER2-positive breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease-Free Survival at 5 years. Started Jun 2023; status: recruiting.
02
Drugs
carboplatin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05883852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05883852.